Search Results

You are looking at 31 - 40 of 113 items for :

  • "consolidation therapy" x
  • Refine by Access: All x
Clear All
Full access

Acute Myeloid Leukemia

Margaret R. O'Donnell, Camille N. Abboud, Jessica Altman, Frederick R. Appelbaum, Steven E. Coutre, Lloyd E. Damon, James M. Foran, Salil Goorha, Lori J. Maness, Guido Marcucci, Peter Maslak, Michael M. Millenson, Joseph O. Moore, Farhad Ravandi, Paul J. Shami, B. Douglas Smith, Richard M. Stone, Stephen A. Strickland, Martin S. Tallman, and Eunice S. Wang

has been divided into induction chemotherapy and postremission (or consolidation) therapy. Although the first step in controlling the disease is to achieve remission, the patient must also emerge from the induction phase able to tolerate subsequent

Full access

Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology

Margaret R. O'Donnell, Martin S. Tallman, Camille N. Abboud, Jessica K. Altman, Frederick R. Appelbaum, Daniel A. Arber, Vijaya Bhatt, Dale Bixby, William Blum, Steven E. Coutre, Marcos De Lima, Amir T. Fathi, Melanie Fiorella, James M. Foran, Steven D. Gore, Aric C. Hall, Patricia Kropf, Jeffrey Lancet, Lori J. Maness, Guido Marcucci, Michael G. Martin, Joseph O. Moore, Rebecca Olin, Deniz Peker, Daniel A. Pollyea, Keith Pratz, Farhad Ravandi, Paul J. Shami, Richard M. Stone, Stephen A. Strickland, Eunice S. Wang, Matthew Wieduwilt, Kristina Gregory, and Ndiya Ogba

placebo or midostaurin (50 mg, twice daily on days 8–22) followed by a year of maintenance therapy with placebo or midostaurin (50 mg, twice daily). 28 Patients who received midostaurin with standard induction and consolidation therapy experienced a

Full access

NCCN Guidelines Insights: T-Cell Lymphomas, Version 1.2021

Featured Updates to the NCCN Guidelines

Steven M. Horwitz, Stephen Ansell, Weiyun Z. Ai, Jeffrey Barnes, Stefan K. Barta, Mark W. Clemens, Ahmet Dogan, Aaron M. Goodman, Gaurav Goyal, Joan Guitart, Ahmad Halwani, Bradley M. Haverkos, Richard T. Hoppe, Eric Jacobsen, Deepa Jagadeesh, Allison Jones, Youn H. Kim, Neha Mehta-Shah, Elise A. Olsen, Barbara Pro, Saurabh A. Rajguru, Sima Rozati, Jonathan Said, Aaron Shaver, Andrei Shustov, Lubomir Sokol, Pallawi Torka, Carlos Torres-Cabala, Ryan Wilcox, Basem M. William, Jasmine Zain, Mary A. Dwyer, and Hema Sundar

Few studies have reported improved survival outcomes with autologous or allogeneic HCT as consolidation therapy for patients with disease in first or second remission. 34 , 42 , 43 Some studies have also reported that graft-versus-lymphoma effect

Full access

Strategies for Management of Relapsed or Refractory Hodgkin Lymphoma

Leo I. Gordon

: 310 – 317 . 3. Moskowitz CH Nademanee A Masszi T . Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double

Full access

Role of Bone Marrow Transplantation in the Disease Pathway of Myeloma

Jean-Luc Harousseau and Philippe Moreau

. Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies . Blood 2006 ; 107 : 2633 – 2638 . 18. Moreau P Hullin C Garban F . Tandem autologous

Full access

NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019

Featured Updates to the NCCN Guidelines

Andrew D. Zelenetz, Leo I. Gordon, Jeremy S. Abramson, Ranjana H. Advani, Nancy L. Bartlett, Paolo F. Caimi, Julie E. Chang, Julio C. Chavez, Beth Christian, Luis E. Fayad, Martha J. Glenn, Thomas M. Habermann, Nancy Lee Harris, Francisco Hernandez-Ilizaliturri, Mark S. Kaminski, Christopher R. Kelsey, Nadia Khan, Susan Krivacic, Ann S. LaCasce, Amitkumar Mehta, Auayporn Nademanee, Rachel Rabinovitch, Nishitha Reddy, Erin Reid, Kenneth B. Roberts, Stephen D. Smith, Erin D. Snyder, Lode J. Swinnen, Julie M. Vose, Mary A. Dwyer, and Hema Sundar

demonstrates continued CD20 expression; however; rituximab may be omitted in patients with primary refractory disease. Consolidation therapy with HDT/ASCR (category 1 for patients with CR) ± radiotherapy (RT) is recommended for patients with CR or PR to second

Full access

Hematopoietic Stem Cell Transplantation in Multiple Myeloma

Jean-Luc Harousseau

Edited by Kerrin G. Robinson

– 3294 . 23 Spencer A Prince HM Roberts A . Consolidation therapy with thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single ASCT procedure . J Clin Oncol 2009 ; 27 : 1788 – 1793 . 24

Full access

PACIFIC: An Ocean of Hope in Patients With Stage III Unresectable Non–Small Cell Lung Cancer

Dipesh Uprety and David E. Marinier

proven. Antonia et al 6 recently reported the results of the phase III PACIFIC trial, which evaluated the role of durvalumab (a selective monoclonal antibody against programmed death-ligand 1 [PD-L1]) as consolidation therapy in patients with stage III

Full access


to first-line therapy have the option of being observed or treated with consolidation therapy. Phase III studies have demonstrated that consolidation with radioimmunotherapy (FIT trial) or rituximab (Rituxan, Genentech BioOncology and Biogen Idec

Full access

Part I: The Role of Maintenance Therapy in Patients With Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation

Philip L. McCarthy

. 12 Cavo M Tacchetti P Patriarca F . Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly